Robert F.G. Booth

Robert F.G. Booth

Auto-generated profile, based on publicly available information

Robert F.G. Booth

ViroBay Inc

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1998 in Cellular Immunology
Verified
Journal Article
Closed access
NWNicola J. Williams
Nicola J. Williams
JHJennifer J. Harvey
Jennifer J. Harvey
IDIan Duncan
Ian Duncan
RBRobert F.G. Booth
Robert F.G. Booth
SKStella C. Knight
Stella C. Knight

1 January 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
RBRyan Brown
Ryan Brown
DSDonna Small
Donna Small
DDDeclan F. Doherty
Declan F. Doherty
LHLeslie Holsinger
Leslie Holsinger
RBRobert Booth
Robert Booth
Sinead WeldonSinead Weldon
Sinead Weldon
Background. Elevated levels of the cysteine protease cathepsin S (CatS) are associated with chronic mucoobstructive lung diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). We have previously demonstrated that prophylactic treatment with a CatS inhibitor from birth reduces inflammation, mucus plugging, and lung tissue damage in juvenile β‐epithelial Na+ channel‐overexpressing transgenic (βENaC‐Tg) mice with chronic inflammatory mucoobstructive lung disease. In this study, we build upon this work to examine the effects of therapeutic intervention with a CatS inhibitor in adult βENaC‐Tg mice with established disease. Methods. βENaC‐Tg mice and wild‐type (WT) littermates were treated with a CatS inhibitor from 4 to 6 weeks of age, and CatS-/-βENaC‐Tg mice were analysed at 6 weeks of age. Bronchoalveolar lavage (BAL) fluid inflammatory cell counts were quantified, and lung tissue destruction and mucus obstruction were analysed histologically. Results. At 6 weeks of age, βENaC‐Tg mice developed significant airway inflammation, lung tissue damage, and mucus plugging when compared to WT mice. CatS-/-βENaC‐Tg mice and βENaC‐Tg mice receiving inhibitor had significantly reduced airway mononuclear and polymorphonuclear (PMN) cell counts as well as mucus plugging. However, in contrast to CatS-/-βENaC‐Tg mice, therapeutic inhibition of CatS in βENaC‐Tg mice had no effect on established emphysema‐like lung tissue damage. Conclusions. These results suggest that while early CatS targeting may be required to prevent the onset and progression of lung tissue damage, therapeutic CatS targeting effectively inhibited airway inflammation and mucus obstruction. These results indicate the important role CatS may play in the pathogenesis and progression of mucoobstructive lung disease.